153 related articles for article (PubMed ID: 34927071)
41. Endocytosis-Mediated Replenishment of Amino Acids Favors Cancer Cell Proliferation and Survival in Chromophobe Renal Cell Carcinoma.
Xiao Y; Rabien A; Buschow R; Amtislavskiy V; Busch J; Kilic E; Villegas SL; Timmermann B; Schütte M; Mielke T; Yaspo ML; Jung K; Meierhofer D
Cancer Res; 2020 Dec; 80(24):5491-5501. PubMed ID: 33115803
[TBL] [Abstract][Full Text] [Related]
42. Progesterone receptor reactivity in renal oncocytoma and chromophobe renal cell carcinoma.
Mai KT; Teo I; Belanger EC; Robertson SJ; Marginean EC; Islam S
Histopathology; 2008 Feb; 52(3):277-82. PubMed ID: 18081814
[TBL] [Abstract][Full Text] [Related]
43. [Correlation of microvascular density and clinicopathological factors in different subtypes of renal cell carcinoma].
Zhang YH; Yang Q; Cui W; Liu YX; Liu SX; Yao X
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):117-22. PubMed ID: 20403242
[TBL] [Abstract][Full Text] [Related]
44. Chromophobe renal cell carcinoma.
Henske EP; Cheng L; Hakimi AA; Choueiri TK; Braun DA
Cancer Cell; 2023 Aug; 41(8):1383-1388. PubMed ID: 37541245
[TBL] [Abstract][Full Text] [Related]
45. Differentiation of subtypes of renal cell carcinoma with contrast-enhanced ultrasonography.
Xue LY; Lu Q; Huang BJ; Li CX; Yan LX; Wang WP
Clin Hemorheol Microcirc; 2016 Oct; 63(4):361-371. PubMed ID: 26598999
[TBL] [Abstract][Full Text] [Related]
46. Mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: a tissue microarray and quantitative RT-PCR study.
Yakirevich E; Morris DJ; Tavares R; Meitner PA; Lechpammer M; Noble L; de Rodriguez AF; Gomez-Sanchez CE; Wang LJ; Sabo E; Delellis RA; Resnick MB
Am J Surg Pathol; 2008 Jun; 32(6):874-83. PubMed ID: 18408592
[TBL] [Abstract][Full Text] [Related]
47. Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.
Stec R; Grala B; Maczewski M; Bodnar L; Szczylik C
J Exp Clin Cancer Res; 2009 Oct; 28(1):134. PubMed ID: 19811659
[TBL] [Abstract][Full Text] [Related]
48. The Utility of ERBB4 and RB1 Immunohistochemistry in Distinguishing Chromophobe Renal Cell Carcinoma From Renal Oncocytoma.
Sun T; Hutchinson L; Zhou AG; Liu Q; Cosar EF; St Cyr M; Ninteau N; Dresser K; Cheng L; Jiang Z; Cornejo KM
Int J Surg Pathol; 2020 May; 28(3):259-264. PubMed ID: 31640438
[No Abstract] [Full Text] [Related]
49. Systemic therapy for chromophobe renal cell carcinoma: A systematic review.
Papanikolaou D; Ioannidou P; Koukourikis P; Moysidis K; Meditskou S; Koutsoumparis D; Hatzimouratidis K; Hatzivassiliou E
Urol Oncol; 2020 Apr; 38(4):137-149. PubMed ID: 31953002
[TBL] [Abstract][Full Text] [Related]
50. Hybrid oncocytic/chromophobe renal cell tumours do not display genomic features of chromophobe renal cell carcinomas.
Poté N; Vieillefond A; Couturier J; Arrufat S; Metzger I; Delongchamps NB; Camparo P; Mège-Lechevallier F; Molinié V; Sibony M
Virchows Arch; 2013 Jun; 462(6):633-8. PubMed ID: 23708994
[TBL] [Abstract][Full Text] [Related]
51. LMP2, a novel immunohistochemical marker to distinguish renal oncocytoma from the eosinophilic variant of chromophobe renal cell carcinoma.
Zheng G; Chaux A; Sharma R; Netto G; Caturegli P
Exp Mol Pathol; 2013 Feb; 94(1):29-32. PubMed ID: 22705098
[TBL] [Abstract][Full Text] [Related]
52. Comparative study of CT appearances in renal oncocytoma and chromophobe renal cell carcinoma.
Wu J; Zhu Q; Zhu W; Chen W; Wang S
Acta Radiol; 2016 Apr; 57(4):500-6. PubMed ID: 25972369
[TBL] [Abstract][Full Text] [Related]
53. Comprehensive Review of Numerical Chromosomal Aberrations in Chromophobe Renal Cell Carcinoma Including Its Variant Morphologies.
Alaghehbandan R; Trpkov K; Tretiakova M; Luis AS; Rogala JD; Hes O
Adv Anat Pathol; 2021 Jan; 28(1):8-20. PubMed ID: 33021507
[TBL] [Abstract][Full Text] [Related]
54. Genetic alterations of HER genes in chromophobe renal cell carcinoma.
Weng WH; Chen YT; Yu KJ; Chang YH; Chuang CK; Pang ST
Oncol Lett; 2016 Mar; 11(3):2111-2116. PubMed ID: 26998131
[TBL] [Abstract][Full Text] [Related]
55. Molecular classification of adult renal epithelial neoplasms using microRNA expression and virtual karyotyping.
Powers MP; Alvarez K; Kim HJ; Monzon FA
Diagn Mol Pathol; 2011 Jun; 20(2):63-70. PubMed ID: 21532496
[TBL] [Abstract][Full Text] [Related]
56. Whole-Lesion CT Texture Analysis as a Quantitative Biomarker for the Identification of Homogeneous Renal Tumors.
Meng X; Li S; Feng C; Hu D; Li Z; Niu Y
Life (Basel); 2022 Dec; 12(12):. PubMed ID: 36556513
[TBL] [Abstract][Full Text] [Related]
57. Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched Analysis.
Frees S; Kamal MM; Knoechlein L; Bell R; Ziesel C; Neisius A; Thomas C; Brenner W; Jäger W; Thüroff JW; Roos FC
Urology; 2016 Dec; 98():81-87. PubMed ID: 27262395
[TBL] [Abstract][Full Text] [Related]
58. [Diagnosis and Treatment of 126 Cases of Chromophobe Renal Cell Carcinoma].
Bai HS; Wang D; Wen L; Shou JZ; Li CL; Xing NZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Apr; 43(2):247-252. PubMed ID: 33966705
[TBL] [Abstract][Full Text] [Related]
59. Subgroup-Independent Mapping of Renal Cell Carcinoma-Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries.
Marquardt A; Solimando AG; Kerscher A; Bittrich M; Kalogirou C; Kübler H; Rosenwald A; Bargou R; Kollmannsberger P; Schilling B; Meierjohann S; Krebs M
Front Oncol; 2021; 11():621278. PubMed ID: 33791209
[No Abstract] [Full Text] [Related]
60. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
